Recommendation comes after recent FDA approval and positive CHMP Opinion for ribociclib (Kisqali) to help reduce the risk of recurrence in EBC. (Image Credits: Pexels) The NCCN Clinical Practice ...

Kisqali ® (ribociclib) is a selective cyclin-dependent kinase inhibitor ... Low white blood cell counts (neutropenia). Low white blood cell counts are very common during treatment with KISQALI and may ...

Their research suggested that neoadjuvant therapy with a combination of ribociclib and letrozole could be an alternative to multi-drug neoadjuvant chemotherapy. The trial involved high risk ...

If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment ...

Some treatments that may be used include: Drugs that stimulate the bone marrow: For chemotherapy-induced neutropenia and some other causes, the growth factors Leukine, Neupogen, Neulasta, or Ryzneuta ...

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

The side effects were similar in both groups, with the most common issues being neutropenia, arthralgia and liver-related events. "Overall, the NATALEE trial supports support ribociclib plus endocrine ...

The neutropenic diet is named after a medical condition called neutropenia. Neutrophils are an important type of white blood cell (WBC) that help fight infection. When the neutrophil count drops ...